Русские видео

Сейчас в тренде

Иностранные видео


Скачать с ютуб SPMS and PPMS are the Same (Multiple Sclerosis is One Disease) [Neurologist Explains] в хорошем качестве

SPMS and PPMS are the Same (Multiple Sclerosis is One Disease) [Neurologist Explains] 1 год назад


Если кнопки скачивания не загрузились НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу страницы.
Спасибо за использование сервиса savevideohd.ru



SPMS and PPMS are the Same (Multiple Sclerosis is One Disease) [Neurologist Explains]

The subtypes of multiple sclerosis such as secondary progressive MS (SPMS) and primary progressive MS (PPMS) are often described as distinct diseases. In fact, clinical trials often recruit people with a specific subtype, and treatment guidelines make a distinction between SPMS and PPMS. I argue that there is no meaningful distinction between SPMS and PPMS and show radiologic, pathologic, and clinical data. Many of these images in my presentation are taken from an EMA workshop presentation in 2013 Selected Sources: Long-term evolution of multiple sclerosis disability in the treatment era: https://pubmed.ncbi.nlm.nih.gov/27464... Clinical development issues in progressive MS: https://www.ema.europa.eu/en/document... Aggregation of multiple sclerosis genetic risk variants in multiple and single case families: https://pubmed.ncbi.nlm.nih.gov/21280... Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes: https://n.neurology.org/content/74/23... Relapsing–remitting and primary progressive MS have the same cause(s) – the neuropathologist’s view: https://journals.sagepub.com/doi/10.1... Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review: https://pubmed.ncbi.nlm.nih.gov/35258... Multiple sclerosis is one disease: https://pubmed.ncbi.nlm.nih.gov/35714... Benefit of interferon β-1a on MSFC progression in secondary progressive MS: https://n.neurology.org/content/59/5/... Comparison of Disease Activity in SPMS and PPMS in the Context of Multicenter Clinical Trials: https://journals.plos.org/plosone/art... Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients: https://www.researchgate.net/figure/D... Comment or ask questions below! I would be happy to answer! Subscribe on YouTube for more videos every Wednesday! Make video requests in the comments section! Check out my book “Resilience in the Face of Multiple Sclerosis” FREE on Amazon: https://amazon.com/dp/B07WP7H5LK It's about 5 people with MS who live incredible lives, the science and psychology of resilience, mindfulness, and ho’oponopono. Paperback priced to generate $0 royalty. Dr. Brandon Beaber is a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system. He is a partner in the Southern California Permanente Medical Group and practices in Downey, California (South Los Angeles). He has several publications on MS epidemiology and has participated in clinical trials for MS therapeutics. You can follow him on twitter @Brandon_Beaber where he regularly posts about MS news and research. Follow me on twitter:   / brandon_beaber   Music: INNER GRACE - Copyright 2018 Wilton Vought Source: Really Really Free Music Link:    • Видео   T he video material by Dr. Brandon Beaber is general educational material on health conditions and is not intended to be used by viewers to diagnose or treat any individual's medical condition. Specifically, this material is not a substitute for individualized diagnostic and treatment advice by a qualified medical/health practitioner, licensed in your jurisdiction, who has access to the relevant information available from diagnostic testing, medical interviews, and a physical examination. To the extent that Dr. Beaber endorses any lifestyle change, behavioral intervention, or supplements, the viewer should consult with a qualified healthcare professional to determine the safety and efficacy of the intervention in light of their individualized information.

Comments